These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 18558283)

  • 1. Anti- and proinflammatory cytokine gene polymorphism and genetic predisposition: association with smoking, tumor stage and grade, and bacillus Calmette-Guérin immunotherapy in bladder cancer.
    Ahirwar D; Kesarwani P; Manchanda PK; Mandhani A; Mittal RD
    Cancer Genet Cytogenet; 2008 Jul; 184(1):1-8. PubMed ID: 18558283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IL-8 -251 T > A polymorphism is associated with bladder cancer susceptibility and outcome after BCG immunotherapy in a northern Indian cohort.
    Ahirwar DK; Mandhani A; Mittal RD
    Arch Med Res; 2010 Feb; 41(2):97-103. PubMed ID: 20470938
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of tumour necrosis factor-alpha gene (T-1031C, C-863A, and C-857T) polymorphisms with bladder cancer susceptibility and outcome after bacille Calmette-Guérin immunotherapy.
    Ahirwar DK; Mandhani A; Dharaskar A; Kesarwani P; Mittal RD
    BJU Int; 2009 Sep; 104(6):867-73. PubMed ID: 19338536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Caspase 9 and caspase 8 gene polymorphisms and susceptibility to bladder cancer in north Indian population.
    Gangwar R; Mandhani A; Mittal RD
    Ann Surg Oncol; 2009 Jul; 16(7):2028-34. PubMed ID: 19412632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polymorphisms of the human NRAMP1 gene are associated with response to bacillus Calmette-Guerin immunotherapy for superficial bladder cancer.
    Decobert M; Larue H; Bergeron A; Harel F; Pfister C; Rousseau F; Lacombe L; Fradet Y
    J Urol; 2006 Apr; 175(4):1506-11. PubMed ID: 16516037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polymorphism within the cyclin D1 gene is associated with an increased risk of carcinoma in situ in patients with superficial bladder cancer.
    Ito M; Habuchi T; Watanabe J; Higashi S; Nishiyama H; Wang L; Tsuchiya N; Kamoto T; Ogawa O
    Urology; 2004 Jul; 64(1):74-8. PubMed ID: 15245939
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patterns of recurrence and outcomes following induction bacillus Calmette-Guerin for high risk Ta, T1 bladder cancer.
    Lerner SP; Tangen CM; Sucharew H; Wood D; Crawford ED
    J Urol; 2007 May; 177(5):1727-31. PubMed ID: 17437798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An analysis of the effect of statin use on the efficacy of bacillus calmette-guerin treatment for transitional cell carcinoma of the bladder.
    Berglund RK; Savage CJ; Vora KC; Kurta JM; Cronin AM
    J Urol; 2008 Oct; 180(4):1297-300; discussion 1300. PubMed ID: 18707737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polymorphisms in inflammation genes and bladder cancer: from initiation to recurrence, progression, and survival.
    Leibovici D; Grossman HB; Dinney CP; Millikan RE; Lerner S; Wang Y; Gu J; Dong Q; Wu X
    J Clin Oncol; 2005 Aug; 23(24):5746-56. PubMed ID: 16110031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term follow-up of patients with Stage T1 high-grade transitional cell carcinoma managed by Bacille Calmette-Guérin immunotherapy.
    Margel D; Tal R; Golan S; Kedar D; Engelstein D; Baniel J
    Urology; 2007 Jan; 69(1):78-82. PubMed ID: 17270621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FASL polymorphism is associated with response to bacillus Calmette-Guérin immunotherapy in bladder cancer.
    Lima L; Ferreira JA; Tavares A; Oliveira D; Morais A; Videira PA; Medeiros R; Santos L
    Urol Oncol; 2014 Jan; 32(1):44.e1-7. PubMed ID: 23948181
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytokine gene polymorphisms are associated with risk of urinary bladder cancer and recurrence after BCG immunotherapy.
    Ahirwar DK; Agrahari A; Mandhani A; Mittal RD
    Biomarkers; 2009 Jun; 14(4):213-8. PubMed ID: 19489682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytokine gene polymorphisms can alter the effect of Bacillus Calmette-Guérin (BCG) immunotherapy.
    Basturk B; Yavascaoglu I; Oral B; Göral G; Oktay B
    Cytokine; 2006 Jul; 35(1-2):1-5. PubMed ID: 16938461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bladder tumor infiltrating mature dendritic cells and macrophages as predictors of response to bacillus Calmette-Guérin immunotherapy.
    Ayari C; LaRue H; Hovington H; Decobert M; Harel F; Bergeron A; Têtu B; Lacombe L; Fradet Y
    Eur Urol; 2009 Jun; 55(6):1386-95. PubMed ID: 19193487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The predictive value of GSTT1 polymorphisms in predicting the early response to induction BCG therapy in patients with non-muscle invasive bladder cancer.
    Kang HW; Tchey DU; Yan C; Kim WT; Kim YJ; Yun SJ; Lee SC; Choi YH; Kim IY; Kim WJ
    Urol Oncol; 2014 May; 32(4):458-65. PubMed ID: 24411789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The results of concurrent chemo-radiotherapy for recurrence after treatment with bacillus Calmette-Guérin for non-muscle-invasive bladder cancer: is immediate cystectomy always necessary?
    Wo JY; Shipley WU; Dahl DM; Coen JJ; Heney NM; Kaufman DS; Zietman AL
    BJU Int; 2009 Jul; 104(2):179-83. PubMed ID: 19154448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polymorphisms in tumor necrosis factor genes and susceptibility to esophageal squamous cell carcinoma and gastric cardiac adenocarcinoma in a population of high incidence region of North China.
    Guo W; Wang N; Li Y; Zhang JH
    Chin Med J (Engl); 2005 Nov; 118(22):1870-8. PubMed ID: 16313841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association.
    Kikuchi E; Fujimoto H; Mizutani Y; Okajima E; Koga H; Hinotsu S; Shinohara N; Oya M; Miki T;
    Int J Urol; 2009 Mar; 16(3):279-86. PubMed ID: 19207609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interleukin-10 G-1082A and C-819T polymorphisms as possible molecular markers of urothelial bladder cancer.
    Ahirwar D; Mandhani A; Mittal RD
    Arch Med Res; 2009 Feb; 40(2):97-102. PubMed ID: 19237018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IL-4 and TNF-α polymorphisms are associated with risk of multiple superficial tumors or carcinoma in situ development.
    Lima L; Silva J; Amaro T; Morais A; Lopes C; Medeiros R; Videira PA; Santos L
    Urol Int; 2011; 87(4):457-63. PubMed ID: 22104567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.